For metastatic MBC, systemic therapy aligns with female breast cancer guidelines: endocrine therapy for hormone-receptor-positive disease, HER2-targeted therapy when indicated, and chemotherapy or immunotherapy based on tumor characteristics and disease burden [9,10]. This evidence concerns the gene ERBB2 and breast cancer.